Common Stock, par value $0.001
- Symbol
- SBFM
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 5.02 · 8-K
Sunshine Biopharma Inc.
SBFMNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 25, 2026, Dr. Andrew Keller, a director of Sunshine Biopharma Inc. (the “Company”), notified the Company that he will not be seeking or accepting reelection to the Board of Directors of the Company upon completion of his current term. Dr.…
Company context
We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc., a Canadian corporation, through which we currently have 60 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc., a Canadian corporation through which we develop and sell OTC supplements.
Current securities
Historical securities (6)
SBFMOTC · EQUITY · Historical · closed Feb 1, 2019SBFMOTC · EQUITY · Historical · closed Apr 6, 2020SBFMOTC · EQUITY · Historical · closed Feb 9, 2022SBFMDOTC · EQUITY · Historical · closed Mar 1, 2019SBFMDOTC · EQUITY · Historical · closed May 1, 2020SBFMDOTC · EQUITY · Historical · closed Feb 15, 2022
Registered securities in this filing
SUNSHINE BIOPHARMA INC. · 8-K · Filed 2026-08-28
Common Stock Purchase Warrants
- Symbol
- SBFMW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 25, 2026, Dr. Andrew Keller, a
director of Sunshine Biopharma Inc. (the “Company”), notified the Company that he will not be seeking or accepting
reelection to the Board of Directors of the Company upon completion of his current term. Dr. Keller’s current term will expire
at the Company’s next annual shareholder meeting.